{"id":5256,"date":"2020-11-04T12:40:00","date_gmt":"2020-11-04T12:40:00","guid":{"rendered":"https:\/\/irlab.se\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/"},"modified":"2020-11-04T12:40:00","modified_gmt":"2020-11-04T12:40:00","slug":"irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa","status":"publish","type":"post","link":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/","title":{"rendered":"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA"},"content":{"rendered":"<p><span><span><span>\u201dFyra veckor efter amerikanska FDA:s godk\u00e4nnande av v\u00e5r IND-ans\u00f6kan startar patientrekryteringen vilket visar p\u00e5 m\u00e5lmedvetenheten i teamets arbete. Mesdopetam kan g\u00f6ra stor skillnad f\u00f6r patienter med Parkinsons sjukdom. Vi tar nu ytterligare ett viktigt steg mot v\u00e5rt m\u00e5l att erbjuda effektiv behandling\u201d, s\u00e4ger Nicholas Waters, VD p\u00e5 IRLAB.<\/span><\/span><\/span><\/p>\n<p><span><span><span>Den kliniska fas IIb\/III-studien med mesdopetam \u00e4r en randomiserad, dubbelblind och placebo-kontrollerad studie med syfte att utv\u00e4rdera effekten av mesdopetam i patienter med Parkinsons sjukdom drabbade av dagliga besv\u00e4rande dyskinesier. <\/span><\/span><\/span><\/p>\n<p><span><span><span>Det prim\u00e4ra utfallsm\u00e5ttet \u00e4r f\u00f6r\u00e4ndringen av den dagliga tiden d\u00e5 patienten har god r\u00f6relsef\u00f6rm\u00e5ga utan besv\u00e4rande dyskinesier (\u201cGood ON\u201d), m\u00e4tt med patientdagbok. Studien \u00e4r planerad att inkludera cirka 140 randomiserade patienter f\u00f6rdelade p\u00e5 fyra grupper med cirka 35 patienter i varje grupp, tre grupper med olika dosniv\u00e5er av mesdopetam och en placebogrupp. Varje patient kommer ha en tre m\u00e5naders behandlingsperiod.<\/span><\/span><\/span><\/p>\n<p><span><span><span>Parallella ans\u00f6kningsprocesser f\u00f6r Fas IIb\/III-studien hos regulatoriska myndigheter och etikkommitt\u00e9er i utvalda europeiska l\u00e4nder p\u00e5g\u00e5r.<\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att rekryteringen av patienter i USA har p\u00e5b\u00f6rjats i Fas IIb\/III-studien med l\u00e4kemedelskandidaten mesdopetam (IRL790) . Mesdopetam utvecklas f\u00f6r behandling av levodopainducerade dyskinesier, PD-LIDs, vid Parkinsons sjukdom med m\u00e5let att \u00f6ka s.k. \u201dgood ON-tid\u201d.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-5256","post","type-post","status-publish","format-standard","hentry","category-pressmeddelande-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB startar Fas IIb\/III-studie med mesdopetam i USA - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att rekryteringen av patienter i USA har p\u00e5b\u00f6rjats i Fas IIb\/III-studien med l\u00e4kemedelskandidaten mesdopetam (IRL790) . Mesdopetam utvecklas f\u00f6r behandling av levodopainducerade dyskinesier, PD-LIDs, vid Parkinsons sjukdom med m\u00e5let att \u00f6ka s.k. \u201dgood ON-tid\u201d.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-04T12:40:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA\",\"datePublished\":\"2020-11-04T12:40:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\"},\"wordCount\":192,\"commentCount\":0,\"articleSection\":[\"Pressmeddelande\"],\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\",\"url\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\",\"name\":\"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2020-11-04T12:40:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA - IRLAB","og_description":"IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att rekryteringen av patienter i USA har p\u00e5b\u00f6rjats i Fas IIb\/III-studien med l\u00e4kemedelskandidaten mesdopetam (IRL790) . Mesdopetam utvecklas f\u00f6r behandling av levodopainducerade dyskinesier, PD-LIDs, vid Parkinsons sjukdom med m\u00e5let att \u00f6ka s.k. \u201dgood ON-tid\u201d.","og_url":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/","og_site_name":"IRLAB","article_published_time":"2020-11-04T12:40:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#article","isPartOf":{"@id":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/"},"author":{"name":"","@id":""},"headline":"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA","datePublished":"2020-11-04T12:40:00+00:00","mainEntityOfPage":{"@id":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/"},"wordCount":192,"commentCount":0,"articleSection":["Pressmeddelande"],"inLanguage":"sv-SE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/","url":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/","name":"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2020-11-04T12:40:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/irlab-startar-fas-iib-iii-studie-med-mesdopetam-i-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"IRLAB startar Fas IIb\/III-studie med mesdopetam i USA"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/5256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=5256"}],"version-history":[{"count":0,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/5256\/revisions"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=5256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/categories?post=5256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/tags?post=5256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}